Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Serum 25(OH)D increased from 19.76 ± 8.68 ng/mL to 38.36 ± 6.35 ng/mL (mean change: 18.60 ng/mL; 95% CI: 16.73 to 20.47; p < 0.001), consistent with vitamin D supplementation (Table 2).

Source: Renal and mineral metabolism outcomes. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Three-year longitudinal assessment of denosumab’s efficacy and safety in postmenopausal osteoporosis: a 36-month real-world cohort study

Source: Article title.

Participants were followed for 36 months with assessments at baseline, 12, 24, and 36 months.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Three-year longitudinal assessment of denosumab’s efficacy and safety in postmenopausal osteoporosis: a 36-month real-world cohort study

Cohort study · Frontiers in Medicine · 2026

Original publication title

Three-year longitudinal assessment of denosumab’s efficacy and safety in postmenopausal osteoporosis: a 36-month real-world cohort study

Rong-Lin Xia; Chen Li; Li Wang; Ai-Jun Chao; Wei Wei

Copyright © 2026 Xia, Li, Wang, Chao and Wei.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Thirty-six months of denosumab treatment was associated with sustained improvement in BMD, suppression of bone turnover, acceptable adherence, and a favorable safety profile in postmenopausal women with osteoporosis who completed the planned 36-month treatment course. Because only patients completing all seven injections with complete follow-up data were included, adherence, persistence, and safety outcomes may be overestimated compared with an intention-to-treat population. These findings support the effectiveness of denosumab under routine clinical practice while emphasizing the importance of continued monitoring and adherence management.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Denosumab is an effective antiresorptive therapy for postmenopausal osteoporosis; however, long-term real-world data regarding sustained efficacy, treatment adherence, safety, and biochemical outcomes remain limited. This study evaluated the 36-month effectiveness and safety of denosumab in postmenopausal women with osteoporosis receiving routine clinical care.

Source: Background

Abstract: What methods does the paper describe?

This retrospective analysis included a prospectively followed real-world clinical cohort of 130 postmenopausal women with osteoporosis treated with denosumab (60 mg subcutaneously every 6 months) plus calcium and vitamin D supplementation. Participants were followed for 36 months with assessments at baseline, 12, 24, and 36 months. Outcomes included bone mineral density (BMD), T-scores, bone turnover markers, renal function, adherence patterns, prior treatment history, fracture occurrence, and adverse events. Changes over time were analyzed using paired longitudinal comparisons and linear mixed-effects models, with significance defined as p < 0.05.

Source: Methods

Abstract: Results

Lumbar spine (L1: L4) BMD increased from 0.674 ± 0.120 to 0.741 ± 0.102 g/cm2, while femoral neck BMD increased from 0.526 ± 0.086 to 0.562 ± 0.079 g/cm2 over 36 months (both p < 0.001). BMD improvements were accompanied by reductions in bone turnover markers, including β-CTX and PINP, indicating sustained suppression of bone resorption. No clinically meaningful renal deterioration was observed during follow-up. Twenty-one participants had prior osteoporosis treatment history, whereas all included patients completed seven denosumab injections.

Delayed injections occurred in 29 patients, although most delays were <30 days. No new fragility fractures occurred during follow-up. No cases of osteonecrosis of the jaw, atypical femoral fracture, or injection-related serious adverse events were observed. Mild hypocalcemia occurred in several patients and resolved with monitoring and supplementation adjustment.

Source: Results

Abstract: Conclusion

Thirty-six months of denosumab treatment was associated with sustained improvement in BMD, suppression of bone turnover, acceptable adherence, and a favorable safety profile in postmenopausal women with osteoporosis who completed the planned 36-month treatment course. Because only patients completing all seven injections with complete follow-up data were included, adherence, persistence, and safety outcomes may be overestimated compared with an intention-to-treat population. These findings support the effectiveness of denosumab under routine clinical practice while emphasizing the importance of continued monitoring and adherence management.

Source: Conclusion
Authors’ abstract

Background

Denosumab is an effective antiresorptive therapy for postmenopausal osteoporosis; however, long-term real-world data regarding sustained efficacy, treatment adherence, safety, and biochemical outcomes remain limited. This study evaluated the 36-month effectiveness and safety of denosumab in postmenopausal women with osteoporosis receiving routine clinical care.

Methods

This retrospective analysis included a prospectively followed real-world clinical cohort of 130 postmenopausal women with osteoporosis treated with denosumab (60 mg subcutaneously every 6 months) plus calcium and vitamin D supplementation. Participants were followed for 36 months with assessments at baseline, 12, 24, and 36 months. Outcomes included bone mineral density (BMD), T-scores, bone turnover markers, renal function, adherence patterns, prior treatment history, fracture occurrence, and adverse events. Changes over time were analyzed using paired longitudinal comparisons and linear mixed-effects models, with significance defined as p < 0.05.

Results

Lumbar spine (L1: L4) BMD increased from 0.674 ± 0.120 to 0.741 ± 0.102 g/cm2, while femoral neck BMD increased from 0.526 ± 0.086 to 0.562 ± 0.079 g/cm2 over 36 months (both p < 0.001). BMD improvements were accompanied by reductions in bone turnover markers, including β-CTX and PINP, indicating sustained suppression of bone resorption. No clinically meaningful renal deterioration was observed during follow-up. Twenty-one participants had prior osteoporosis treatment history, whereas all included patients completed seven denosumab injections.

Delayed injections occurred in 29 patients, although most delays were <30 days. No new fragility fractures occurred during follow-up. No cases of osteonecrosis of the jaw, atypical femoral fracture, or injection-related serious adverse events were observed. Mild hypocalcemia occurred in several patients and resolved with monitoring and supplementation adjustment.

Conclusion

Thirty-six months of denosumab treatment was associated with sustained improvement in BMD, suppression of bone turnover, acceptable adherence, and a favorable safety profile in postmenopausal women with osteoporosis who completed the planned 36-month treatment course. Because only patients completing all seven injections with complete follow-up data were included, adherence, persistence, and safety outcomes may be overestimated compared with an intention-to-treat population. These findings support the effectiveness of denosumab under routine clinical practice while emphasizing the importance of continued monitoring and adherence management.

Publication and source details

Original title: Three-year longitudinal assessment of denosumab’s efficacy and safety in postmenopausal osteoporosis: a 36-month real-world cohort study

Rong-Lin Xia; Chen Li; Li Wang; Ai-Jun Chao; Wei Wei

Frontiers in Medicine · 2026

* Correspondence: Ai-Jun Chao, ajoinmail@126.com; Wei Wei, TJwei2000@126.comCopyright © 2026 Xia, Li, Wang, Chao and Wei.2026Xia, Li, Wang, Chao and Weihttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. National Key Research and Development Plan 2022YFC36019042022YFC3601900The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the National Key Research and Development Plan (2022YFC3601900 and 2022YFC3601904).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:07:15.652234+00:00

DOI: 10.3389/fmed.2026.1825383 · PMC13407513